Will the Cabinet Secretary confirm whether the combination treatment of dabrafenib and trametinib to treat childhood gliomas is available for patients treated in Wales following its recent approval by NICE?
Answered by Cabinet Secretary for Health and Social Care | Answered on 29/10/2024
All treatments recommended by NICE or our own appraisal body the All Wales Medicines Strategy Group (AWMSG) are available to prescribe in Wales.
Dabrafenib and trametinib was made available for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977) on 3 July via the New Treatment Fund.